巴雷特食管完全根除肠化生后复发罕见且高峰在18个月
该前瞻性研究纳入807例接受内镜根除治疗并达到完全根除肠化生(CE-IM)的巴雷特食管(BE)患者,随访至5年。结果显示肠化生复发率15%(5.2/100人年),异型增生复发率5.1%(1.8/100人年),复发高峰在CE-IM后1.6年。基线高级别异型增生或黏膜内癌、反流症状、食管裂孔疝及达到CE-IM所需次数与复发相关。
要点
- CE-IM后肠化生复发率15%,异型增生复发率5.1%,总体复发率低。
- 复发高峰在CE-IM后1.6年,1年后激进监测可能非必要。
- 基线高级别异型增生/黏膜内癌、反流症状、食管裂孔疝及CE-IM所需次数多与复发相关。
核心结论
- 巴雷特食管患者达到完全根除肠化生后复发率低,复发高峰在CE-IM后1-2年。
- CE-IM后1年以上激进监测可能非必要,应纳入监测指南考虑。
研究设计与样本
- 前瞻性研究,纳入807例接受内镜根除治疗并达到CE-IM的巴雷特食管患者。
- 来自4家三级转诊中心,2013年1月至2018年10月。
- 采用Kaplan-Meier估计CE-IM后5年累计复发率,按基线组织学分层。
- 使用逻辑回归分析识别与复发相关的因素。
主要发现
- 中位随访2317人年期间,121例(15%;IR 5.2/100人年)肠化生复发。
- 41例(5.1%;IR 1.8/100人年)异型增生复发。
- 复发率不恒定,任何复发的时间分布趋近正态,高峰在CE-IM后1.6年。
- 基线高级别异型增生或黏膜内癌与复发相关(aOR 4.19)。
- 反流症状(aOR 12.1)、食管裂孔疝(aOR 13.8)及达到CE-IM所需次数(aOR 1.8)与复发相关。
关键数值与推荐
- 肠化生复发率15%(IR 5.2/100人年),异型增生复发率5.1%(IR 1.8/100人年)。
- 复发高峰在CE-IM后1.6年。
- 基线高级别异型增生或黏膜内癌aOR 4.19,反流症状aOR 12.1,食管裂孔疝aOR 13.8,CE-IM所需次数aOR 1.8。
临床怎么用
- CE-IM后1年以上可考虑放宽监测频率,避免过度激进监测。
- 对基线高级别异型增生/黏膜内癌、反流症状、食管裂孔疝及CE-IM所需次数多的患者应加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: There have been few studies describing the long-term durability of complete eradication of intestinal metaplasia (CE-IM) in patients with Barrett's esophagus (BE)-related neoplasia who received endoscopic eradication therapy (EET). Data are needed to guide surveillance interval protocols and identify patients at risk for recurrence. We assessed the rate of recurrence of intestinal metaplasia and dysplasia, histologic features, and outcomes after recurrence of CE-IM, and identified factors associated with recurrence. METHODS: We performed a prospective study of 807 patients with BE who underwent EET, which produced CE-IM, at 4 tertiary-care referral centers, from January 2013 to October 2018. Kaplan-Meier estimates of cumulative incidence rates (IR) of recurrence were calculated for up to 5 years following CE-IM and were stratified by baseline level of histology. Density estimates of recurrence were used to determine the change in the rate of recurrence over time. We conducted logistic regression analysis to identify factors associated with recurrence. RESULTS: Intestinal metaplasia recurred in 121 patients (15%; IR, 5.2/100 person-years), and dysplasia recurred in 41 patients (5.1%; IR, 1.8/100 person-years), after a median follow-up time of 2317 person-years. The rate of recurrence was not constant and the time to any recurrence converged to a normal distribution; recurrences peaked at 1.6 y after patients had CE-IM. Baseline high-grade dysplasia or intramucosal cancer (adjusted odds ratio [aOR], 4.19), presence of reflux symptoms (aOR, 12.1) or hiatal hernia (aOR, 13.8), and number of sessions required to achieve CE-IM (aOR, 1.8) were associated with recurrence. CONCLUSIONS: In a prospective study of a large cohort of patients with BE undergoing EET, we found a low rate of recurrence after CE-IM. The rate of recurrence peaked at 1-2 y after CE-IM. These findings indicate that aggressive surveillance might not be necessary more than 1 y after CE-IM and should be considered in surveillance guidelines. Clinicaltrials.gov no: NCT02634645.
引用
- Wani S, Han S, Kushnir V, et al. Recurrence Is Rare Following Complete Eradication of Intestinal Metaplasia in Patients With Barrett's Esophagus and Peaks at 18 Months. Clin Gastroenterol Hepatol. 2020. PMID: 31982610. doi:10.1016/j.cgh.2020.01.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。